Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape PART II (White Paper)

White Paper

December 17, 2020

Download pdf

This past summer, we released the first installment of our Novel Cell
Type Platforms series ( link ) in which 3 innovative companies were
profiled, each with platforms comprised of distinct cell types ( Kiadis
Pharma NK cells, Incysus Therapeutics gamma delta T cells, and
Kuur Therapeutics NKT cells). The field continues to advance with
dizzying rapidity (e.g., Kiadis was acquired by Sanofi in November, and
Incysus, which changed its name to IN8bio in August, set terms for a
$75M IPO in November).